Rhabdomyosarcoma

News alerts, weekly reports and conference planners

Related cancers:

No biomarker	Rhabdomyosarcoma	No biomarker	Rhabdomyosarcoma	dactinomycin Sensitive: A1 - Approval dactinomycin Sensitive : A1	dactinomycin Sensitive: A1 - Approval dactinomycin Sensitive : A1
No biomarker	Rhabdomyosarcoma	No biomarker	Rhabdomyosarcoma	IE Sensitive: A2 - Guideline IE Sensitive : A2	IE Sensitive: A2 - Guideline IE Sensitive : A2
No biomarker	Rhabdomyosarcoma	No biomarker	Rhabdomyosarcoma	VAC Sensitive: A2 - Guideline VAC Sensitive : A2	VAC Sensitive: A2 - Guideline VAC Sensitive : A2
No biomarker	Rhabdomyosarcoma	No biomarker	Rhabdomyosarcoma	doxorubicin hydrochloride + cyclophosphamide + etoposide IV + vincristine Sensitive: A2 - Guideline doxorubicin hydrochloride + cyclophosphamide + etoposide IV + vincristine Sensitive : A2	doxorubicin hydrochloride + cyclophosphamide + etoposide IV + vincristine Sensitive: A2 - Guideline doxorubicin hydrochloride + cyclophosphamide + etoposide IV + vincristine Sensitive : A2
No biomarker	Rhabdomyosarcoma	No biomarker	Rhabdomyosarcoma	trabectedin Sensitive: A2 - Guideline trabectedin Sensitive : A2	trabectedin Sensitive: A2 - Guideline trabectedin Sensitive : A2
No biomarker	Rhabdomyosarcoma	No biomarker	Rhabdomyosarcoma	methotrexate Sensitive: A2 - Guideline methotrexate Sensitive : A2	methotrexate Sensitive: A2 - Guideline methotrexate Sensitive : A2
No biomarker	Rhabdomyosarcoma	No biomarker	Rhabdomyosarcoma	vinorelbine Sensitive: A2 - Guideline vinorelbine Sensitive : A2	vinorelbine Sensitive: A2 - Guideline vinorelbine Sensitive : A2
No biomarker	Rhabdomyosarcoma	No biomarker	Rhabdomyosarcoma	topotecan Sensitive: A2 - Guideline topotecan Sensitive : A2	topotecan Sensitive: A2 - Guideline topotecan Sensitive : A2
No biomarker	Rhabdomyosarcoma	No biomarker	Rhabdomyosarcoma	irinotecan Sensitive: A2 - Guideline irinotecan Sensitive : A2	irinotecan Sensitive: A2 - Guideline irinotecan Sensitive : A2
No biomarker	Rhabdomyosarcoma	No biomarker	Rhabdomyosarcoma	SA033 Sensitive: A2 - Guideline SA033 Sensitive : A2	SA033 Sensitive: A2 - Guideline SA033 Sensitive : A2
No biomarker	Rhabdomyosarcoma	No biomarker	Rhabdomyosarcoma	temozolomide + irinotecan + vincristine Sensitive: A2 - Guideline temozolomide + irinotecan + vincristine Sensitive : A2	temozolomide + irinotecan + vincristine Sensitive: A2 - Guideline temozolomide + irinotecan + vincristine Sensitive : A2
No biomarker	Rhabdomyosarcoma	No biomarker	Rhabdomyosarcoma	cyclophosphamide + vinorelbine tartrate Sensitive: A2 - Guideline cyclophosphamide + vinorelbine tartrate Sensitive : A2	cyclophosphamide + vinorelbine tartrate Sensitive: A2 - Guideline cyclophosphamide + vinorelbine tartrate Sensitive : A2
No biomarker	Rhabdomyosarcoma	No biomarker	Rhabdomyosarcoma	carboplatin + etoposide oral Sensitive: A2 - Guideline carboplatin + etoposide oral Sensitive : A2	carboplatin + etoposide oral Sensitive: A2 - Guideline carboplatin + etoposide oral Sensitive : A2
No biomarker	Rhabdomyosarcoma	No biomarker	Rhabdomyosarcoma	vincristine + dactinomycin Sensitive: A2 - Guideline vincristine + dactinomycin Sensitive : A2	vincristine + dactinomycin Sensitive: A2 - Guideline vincristine + dactinomycin Sensitive : A2
No biomarker	Rhabdomyosarcoma	No biomarker	Rhabdomyosarcoma	irinotecan + vincristine Sensitive: A2 - Guideline irinotecan + vincristine Sensitive : A2	irinotecan + vincristine Sensitive: A2 - Guideline irinotecan + vincristine Sensitive : A2
No biomarker	Rhabdomyosarcoma	No biomarker	Rhabdomyosarcoma	doxorubicin hydrochloride + ifosfamide Sensitive: A2 - Guideline doxorubicin hydrochloride + ifosfamide Sensitive : A2	doxorubicin hydrochloride + ifosfamide Sensitive: A2 - Guideline doxorubicin hydrochloride + ifosfamide Sensitive : A2
No biomarker	Rhabdomyosarcoma	No biomarker	Rhabdomyosarcoma	cyclophosphamide + topotecan Sensitive: A2 - Guideline cyclophosphamide + topotecan Sensitive : A2	cyclophosphamide + topotecan Sensitive: A2 - Guideline cyclophosphamide + topotecan Sensitive : A2
No biomarker	Rhabdomyosarcoma	No biomarker	Rhabdomyosarcoma	doxorubicin hydrochloride + ifosfamide + vincristine Sensitive: A2 - Guideline doxorubicin hydrochloride + ifosfamide + vincristine Sensitive : A2	doxorubicin hydrochloride + ifosfamide + vincristine Sensitive: A2 - Guideline doxorubicin hydrochloride + ifosfamide + vincristine Sensitive : A2
No biomarker	Rhabdomyosarcoma	No biomarker	Rhabdomyosarcoma	doxorubicin hydrochloride + ifosfamide + cyclophosphamide + vincristine Sensitive: A2 - Guideline doxorubicin hydrochloride + ifosfamide + cyclophosphamide + vincristine Sensitive : A2	doxorubicin hydrochloride + ifosfamide + cyclophosphamide + vincristine Sensitive: A2 - Guideline doxorubicin hydrochloride + ifosfamide + cyclophosphamide + vincristine Sensitive : A2
PD-L1 expression	Rhabdomyosarcoma	PD-L1 expression	Rhabdomyosarcoma	nivolumab Sensitive: C1 - Off-label nivolumab Sensitive : C1	nivolumab Sensitive: C1 - Off-label nivolumab Sensitive : C1
BRAF-MAD1L1 fusion	Rhabdomyosarcoma	BRAF-MAD1L1 fusion	Rhabdomyosarcoma	anlotinib Resistant: C4 – Case Studies anlotinib Resistant : C4	anlotinib Resistant: C4 – Case Studies anlotinib Resistant : C4
PD-L1 expression	Rhabdomyosarcoma	PD-L1 expression	Rhabdomyosarcoma	pazopanib Resistant: C4 – Case Studies pazopanib Resistant : C4	pazopanib Resistant: C4 – Case Studies pazopanib Resistant : C4
EWSR1-TFCP2 fusion	Rhabdomyosarcoma	EWSR1-TFCP2 fusion	Rhabdomyosarcoma	crizotinib Resistant: C4 – Case Studies crizotinib Resistant : C4	crizotinib Resistant: C4 – Case Studies crizotinib Resistant : C4
HRAS mutation	Rhabdomyosarcoma	HRAS mutation	Rhabdomyosarcoma	tipifarnib Sensitive: D – Preclinical tipifarnib Sensitive : D	tipifarnib Sensitive: D – Preclinical tipifarnib Sensitive : D
KDM1A overexpression	Rhabdomyosarcoma	KDM1A overexpression	Rhabdomyosarcoma	SP2577 Sensitive: D – Preclinical SP2577 Sensitive : D	SP2577 Sensitive: D – Preclinical SP2577 Sensitive : D
PAX3-FOXO1 fusion	Rhabdomyosarcoma	PAX3-FOXO1 fusion	Rhabdomyosarcoma	SNDX-275 Sensitive: D – Preclinical SNDX-275 Sensitive : D	SNDX-275 Sensitive: D – Preclinical SNDX-275 Sensitive : D
HER-2 expression	Rhabdomyosarcoma	HER-2 expression	Rhabdomyosarcoma	T-lymphocyte cell therapy Sensitive: D – Preclinical T-lymphocyte cell therapy Sensitive : D	T-lymphocyte cell therapy Sensitive: D – Preclinical T-lymphocyte cell therapy Sensitive : D
HRAS mutation	Rhabdomyosarcoma	HRAS mutation	Rhabdomyosarcoma	trametinib + tipifarnib Sensitive: D – Preclinical trametinib + tipifarnib Sensitive : D	trametinib + tipifarnib Sensitive: D – Preclinical trametinib + tipifarnib Sensitive : D
RAS mutation	Rhabdomyosarcoma	RAS mutation	Rhabdomyosarcoma	trametinib + AMG 479 Sensitive: D – Preclinical trametinib + AMG 479 Sensitive : D	trametinib + AMG 479 Sensitive: D – Preclinical trametinib + AMG 479 Sensitive : D

Rhabdomyosarcoma

Associations(29)

Associations
(29)